Propranolol for treatment of ulcerated infantile hemangiomas
Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. Objective To evaluate our experience of propranolol in the management of ulcerated IH. Methods A national, multicenter, retrospe...
Saved in:
Published in | Journal of the American Academy of Dermatology Vol. 64; no. 5; pp. 827 - 832 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Mosby, Inc
01.05.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. Objective To evaluate our experience of propranolol in the management of ulcerated IH. Methods A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews. Results Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations ( P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases. Limitations This was a retrospective uncontrolled study. Conclusion Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH. |
---|---|
AbstractList | Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH.
To evaluate our experience of propranolol in the management of ulcerated IH.
A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews.
Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations (P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases.
This was a retrospective uncontrolled study.
Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH. Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. To evaluate our experience of propranolol in the management of ulcerated IH. A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews. Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations ( P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases. This was a retrospective uncontrolled study. Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH. Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. Objective To evaluate our experience of propranolol in the management of ulcerated IH. Methods A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews. Results Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations ( P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases. Limitations This was a retrospective uncontrolled study. Conclusion Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH. BACKGROUNDUlcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH.OBJECTIVETo evaluate our experience of propranolol in the management of ulcerated IH.METHODSA national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews.RESULTSThirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations (P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases.LIMITATIONSThis was a retrospective uncontrolled study.CONCLUSIONPropranolol appears to be an effective and well-tolerated treatment for ulcerated IH. |
Author | Naouri, Michaël, MD Stalder, Jean-François, MD Bodak, Nathalie, MD Lacour, Jean-Philippe, MD Léauté-Labrèze, Christine, MD Hadj-Rabia, Smail, MD Vabres, Pierre, MD Nguyen, Jean-Michel, MD Hamel-Teillac, Dominique, MD Barbarot, Sébastien, MD Saint-Jean, Mélanie, MD Kupfer-Bessaguet, Ingrid, MD Mazereeuw-Hautier, Juliette, MD |
Author_xml | – sequence: 1 fullname: Saint-Jean, Mélanie, MD – sequence: 2 fullname: Léauté-Labrèze, Christine, MD – sequence: 3 fullname: Mazereeuw-Hautier, Juliette, MD – sequence: 4 fullname: Bodak, Nathalie, MD – sequence: 5 fullname: Hamel-Teillac, Dominique, MD – sequence: 6 fullname: Kupfer-Bessaguet, Ingrid, MD – sequence: 7 fullname: Lacour, Jean-Philippe, MD – sequence: 8 fullname: Naouri, Michaël, MD – sequence: 9 fullname: Vabres, Pierre, MD – sequence: 10 fullname: Hadj-Rabia, Smail, MD – sequence: 11 fullname: Nguyen, Jean-Michel, MD – sequence: 12 fullname: Stalder, Jean-François, MD – sequence: 13 fullname: Barbarot, Sébastien, MD |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24117933$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21353332$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU2LFDEQhoOsuLOjf8CD9EX21GM-utMdWIRl8WNhQUE9h5p0RdOmkzHpXth_b5oZFTzsqSA8b6XqqQtyFmJAQl4yumOUyTfjbgQYdpyuD3xHG_qEbBhVXS27vjsjG8oUrZXk_Jxc5DxSSlUjumfknDPRCiH4hlx9TvGQIEQffWVjquaEME8Y5iraavEGE8w4VC5YCLPzWP3ACcJ3FyfIz8lTCz7ji1Pdkm_v3329-Vjfffpwe3N9V5umoXMNA3TKqBYE7xur9kx1fUNND7Q1rbEc2g4oDkxYyWTbcyEaUNKowbac9XYvtuTy2PeQ4q8F86wnlw16DwHjknUvuSzLUVZIfiRNijkntPqQ3ATpQTOqV2l61Ks0vUrTjOsirYRendov-wmHv5E_lgrw-gRANuBt8WVc_sc1jHWqkFtydeSwyLh3mHQ2DoPBwSU0sx6ie3yOt__FjXfBlR9_4gPmMS4pFM2a6VwC-st63vW6jK27y178Bq5UoBc |
CODEN | JAADDB |
CitedBy_id | crossref_primary_10_1007_s13312_013_0098_9 crossref_primary_10_1007_s00112_011_2428_0 crossref_primary_10_1016_j_coms_2023_09_003 crossref_primary_10_1056_NEJMoa1404710 crossref_primary_10_1111_j_1525_1470_2011_01615_x crossref_primary_10_1111_pde_15444 crossref_primary_10_1007_s13671_012_0026_6 crossref_primary_10_1016_j_jaad_2014_01_905 crossref_primary_10_1111_j_1468_3083_2011_04105_x crossref_primary_10_1111_bjd_14687 crossref_primary_10_25259_CSDM_257_2023 crossref_primary_10_7759_cureus_16683 crossref_primary_10_1097_GOX_0000000000000605 crossref_primary_10_1542_peds_2015_2485 crossref_primary_10_1016_j_ad_2012_03_010 crossref_primary_10_1111_pde_13372 crossref_primary_10_1007_s00247_016_3643_6 crossref_primary_10_1016_j_anpedi_2015_04_007 crossref_primary_10_1007_s00247_017_4042_3 crossref_primary_10_1007_s10006_015_0528_z crossref_primary_10_1016_j_arcped_2015_01_001 crossref_primary_10_1016_j_coms_2023_09_010 crossref_primary_10_1371_journal_pone_0138100 crossref_primary_10_1111_j_1600_0560_2012_01913_x crossref_primary_10_1097_JDN_0000000000000645 crossref_primary_10_1007_s12519_013_0427_z crossref_primary_10_1111_j_1529_8019_2012_01481_x crossref_primary_10_1111_pde_12089 crossref_primary_10_1016_j_clindermatol_2014_02_002 crossref_primary_10_1016_S0151_9638_11_70098_9 crossref_primary_10_1111_bjd_12436 crossref_primary_10_1111_1346_8138_15189 crossref_primary_10_1016_j_bjoms_2016_02_031 crossref_primary_10_1016_j_jpeds_2016_04_069 crossref_primary_10_1177_1203475418770570 crossref_primary_10_1007_s11604_019_00885_5 crossref_primary_10_1016_j_adengl_2012_01_015 crossref_primary_10_1016_j_adengl_2012_03_020 crossref_primary_10_1016_j_arcped_2013_03_020 crossref_primary_10_1097_SAP_0000000000003206 crossref_primary_10_1016_j_jmv_2014_06_001 crossref_primary_10_3389_fped_2023_1073090 crossref_primary_10_1007_s12519_018_0137_7 crossref_primary_10_1111_pde_12869 crossref_primary_10_3928_00904481_20120727_10 crossref_primary_10_1053_j_semperi_2012_11_003 crossref_primary_10_1002_jcu_22471 crossref_primary_10_1542_neo_16_1_e16 crossref_primary_10_1542_peds_2016_0353 crossref_primary_10_11131_2014_101041 crossref_primary_10_1016_j_therap_2020_02_007 crossref_primary_10_1016_j_jaad_2013_03_002 crossref_primary_10_1016_S1761_2896_18_88284_X crossref_primary_10_1002_hed_24308 crossref_primary_10_1016_S0140_6736_16_00645_0 crossref_primary_10_1111_jpc_12600 crossref_primary_10_1016_j_anpede_2015_10_014 crossref_primary_10_1016_j_pharma_2014_03_001 crossref_primary_10_1001_jamadermatol_2021_0469 crossref_primary_10_1016_j_pepo_2012_11_009 crossref_primary_10_1002_med_21984 crossref_primary_10_1007_s10103_012_1220_2 crossref_primary_10_1542_peds_2012_1691 crossref_primary_10_1111_j_1365_2230_2012_04397_x crossref_primary_10_1007_s40272_013_0008_6 crossref_primary_10_1016_j_bjps_2013_07_035 crossref_primary_10_1016_j_pcl_2013_11_010 crossref_primary_10_1016_j_ad_2011_05_003 crossref_primary_10_1016_j_lfs_2014_02_007 crossref_primary_10_2310_7750_2012_12037 crossref_primary_10_1016_S1245_1789_15_70116_2 crossref_primary_10_1111_bjd_12417 crossref_primary_10_1111_ped_14077 |
Cites_doi | 10.1111/j.1525-1470.2008.00781_2.x 10.1016/j.jpeds.2007.04.055 10.1001/archderm.140.8.963 10.1111/j.1365-2133.2010.09848.x 10.1001/archderm.136.5.628 10.1001/archderm.138.12.1567 10.1067/mjd.2001.112382 10.1684/ejd.2008.0576 10.1542/peds.2008-3458 10.1056/NEJMc0708819 |
ContentType | Journal Article |
Copyright | American Academy of Dermatology, Inc. 2011 American Academy of Dermatology, Inc. 2015 INIST-CNRS Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. |
Copyright_xml | – notice: American Academy of Dermatology, Inc. – notice: 2011 American Academy of Dermatology, Inc. – notice: 2015 INIST-CNRS – notice: Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. |
CorporateAuthor | Groupe de Recherche Clinique en Dermatologie Pédiatrique |
CorporateAuthor_xml | – name: Groupe de Recherche Clinique en Dermatologie Pédiatrique |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.jaad.2010.12.040 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6787 |
EndPage | 832 |
ExternalDocumentID | 10_1016_j_jaad_2010_12_040 21353332 24117933 S0190962211000168 1_s2_0_S0190962211000168 |
Genre | Multicenter Study Journal Article |
GroupedDBID | --- --K --M -RU .1- .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8F7 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HX~ HZ~ IHE J1W J5H KOM LZ2 M27 M41 MO0 N9A O-L O9- OAUVE OB. OBH OHH OM~ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SEL SES SJN SPCBC SSH SSZ T5K TEORI UHS UNMZH UV1 WOW WUQ Y6R YFH Z5R ZCG ZGI ZY1 ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR 08R ABPIF IQODW CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 |
ID | FETCH-LOGICAL-c440t-ada79c95a3284f9b197840c8a05c5cf2a57a0ed13f616582334a96c9df5218fb3 |
IEDL.DBID | AIKHN |
ISSN | 0190-9622 |
IngestDate | Fri Oct 25 00:48:40 EDT 2024 Fri Dec 06 04:43:44 EST 2024 Sat Sep 28 07:50:55 EDT 2024 Sun Oct 22 16:06:55 EDT 2023 Fri Feb 23 02:33:24 EST 2024 Tue Oct 15 22:54:59 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | ulceration FPDL flashlamp pulsed-dye laser (therapy) infantile hemangioma propranolol IH Human Vascular disease Angioma Treatment Dermatology Cardiovascular disease Antiarrhythmic agent Propranolol Ulceration Child |
Language | English |
License | CC BY 4.0 Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c440t-ada79c95a3284f9b197840c8a05c5cf2a57a0ed13f616582334a96c9df5218fb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21353332 |
PQID | 862600001 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_862600001 crossref_primary_10_1016_j_jaad_2010_12_040 pubmed_primary_21353332 pascalfrancis_primary_24117933 elsevier_sciencedirect_doi_10_1016_j_jaad_2010_12_040 elsevier_clinicalkeyesjournals_1_s2_0_S0190962211000168 |
PublicationCentury | 2000 |
PublicationDate | 2011-05-01 |
PublicationDateYYYYMMDD | 2011-05-01 |
PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Journal of the American Academy of Dermatology |
PublicationTitleAlternate | J Am Acad Dermatol |
PublicationYear | 2011 |
Publisher | Mosby, Inc Elsevier |
Publisher_xml | – name: Mosby, Inc – name: Elsevier |
References | Chiller, Passaro, Frieden (bib6) 2002; 138 Chamlin, Haggstrom, Drolet, Baselga, Frieden, Garzon (bib9) 2007; 151 Sans, Dumas de la Roque, Berge, Grenier, Boralevi, Mazereeuw-Hautier (bib5) 2009; 124 Léauté-Labrèze, Dumas de la Roque, Hubiche, Boralevi, Thambo, Taïeb (bib4) 2008; 358 Morelli, Tan, Weston (bib12) 1991; 145 George, Sharma, Jacobson, Simon, Nopper (bib3) 2004; 140 Storch, Hoeger (bib7) 2010; 163 Kim, Colombo, Frieden (bib1) 2001; 44 Hermans, Boezeman, Van de Kerkhof, Rieu, Van der Vleuten (bib10) 2009; 19 Poetke, Philipp, Berlien (bib11) 2000; 136 Yan (bib2) 2008; 25 Mohammadi, Bakhshaeekia, Alibeigi, Hasheminasab, Tolide-ei, Tavakkolian (bib8) 2009; 30 Mohammadi (10.1016/j.jaad.2010.12.040_bib8) 2009; 30 Chamlin (10.1016/j.jaad.2010.12.040_bib9) 2007; 151 Poetke (10.1016/j.jaad.2010.12.040_bib11) 2000; 136 Kim (10.1016/j.jaad.2010.12.040_bib1) 2001; 44 Sans (10.1016/j.jaad.2010.12.040_bib5) 2009; 124 Chiller (10.1016/j.jaad.2010.12.040_bib6) 2002; 138 George (10.1016/j.jaad.2010.12.040_bib3) 2004; 140 Hermans (10.1016/j.jaad.2010.12.040_bib10) 2009; 19 Yan (10.1016/j.jaad.2010.12.040_bib2) 2008; 25 Storch (10.1016/j.jaad.2010.12.040_bib7) 2010; 163 Léauté-Labrèze (10.1016/j.jaad.2010.12.040_bib4) 2008; 358 Morelli (10.1016/j.jaad.2010.12.040_bib12) 1991; 145 |
References_xml | – volume: 44 start-page: 962 year: 2001 end-page: 972 ident: bib1 article-title: Ulcerated hemangiomas: clinical characteristics and response to therapy publication-title: J Am Acad Dermatol contributor: fullname: Frieden – volume: 140 start-page: 963 year: 2004 end-page: 969 ident: bib3 article-title: Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas publication-title: Arch Dermatol contributor: fullname: Nopper – volume: 124 start-page: 423 year: 2009 end-page: 431 ident: bib5 article-title: Propranolol for severe infantile hemangiomas: follow-up report publication-title: Pediatrics contributor: fullname: Mazereeuw-Hautier – volume: 30 start-page: 1013 year: 2009 end-page: 1017 ident: bib8 article-title: Efficacy of propranolol in wound healing for hospitalized burn patients publication-title: J Burn Care Res contributor: fullname: Tavakkolian – volume: 358 start-page: 2649 year: 2008 end-page: 2651 ident: bib4 article-title: Propranolol for severe hemangiomas of infancy publication-title: N Engl J Med contributor: fullname: Taïeb – volume: 136 start-page: 628 year: 2000 end-page: 632 ident: bib11 article-title: Flashlamp-pumped pulsed dye laser for hemangiomas in infancy publication-title: Arch Dermatol contributor: fullname: Berlien – volume: 25 start-page: 586 year: 2008 end-page: 589 ident: bib2 article-title: Pain management for ulcerated hemangiomas publication-title: Pediatr Dermatol contributor: fullname: Yan – volume: 145 start-page: 1062 year: 1991 end-page: 1064 ident: bib12 article-title: Treatment of ulcerated hemangiomas with the pulsed tunable dye laser publication-title: Am J Dis Child contributor: fullname: Weston – volume: 138 start-page: 1567 year: 2002 end-page: 1576 ident: bib6 article-title: Hemangiomas of infancy: clinical characteristics, morphologic subtypes and their relationship to race, ethnicity and sex publication-title: Arch Dermatol contributor: fullname: Frieden – volume: 163 start-page: 269 year: 2010 end-page: 274 ident: bib7 article-title: Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action publication-title: Br J Dermatol contributor: fullname: Hoeger – volume: 151 start-page: 684 year: 2007 end-page: 689 ident: bib9 article-title: Multicenter prospective study of ulcerated hemangiomas publication-title: J Pediatr contributor: fullname: Garzon – volume: 19 start-page: 152 year: 2009 end-page: 156 ident: bib10 article-title: Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases publication-title: Eur J Dermatol contributor: fullname: Van der Vleuten – volume: 25 start-page: 586 year: 2008 ident: 10.1016/j.jaad.2010.12.040_bib2 article-title: Pain management for ulcerated hemangiomas publication-title: Pediatr Dermatol doi: 10.1111/j.1525-1470.2008.00781_2.x contributor: fullname: Yan – volume: 151 start-page: 684 year: 2007 ident: 10.1016/j.jaad.2010.12.040_bib9 article-title: Multicenter prospective study of ulcerated hemangiomas publication-title: J Pediatr doi: 10.1016/j.jpeds.2007.04.055 contributor: fullname: Chamlin – volume: 145 start-page: 1062 year: 1991 ident: 10.1016/j.jaad.2010.12.040_bib12 article-title: Treatment of ulcerated hemangiomas with the pulsed tunable dye laser publication-title: Am J Dis Child contributor: fullname: Morelli – volume: 140 start-page: 963 year: 2004 ident: 10.1016/j.jaad.2010.12.040_bib3 article-title: Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas publication-title: Arch Dermatol doi: 10.1001/archderm.140.8.963 contributor: fullname: George – volume: 163 start-page: 269 year: 2010 ident: 10.1016/j.jaad.2010.12.040_bib7 article-title: Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2010.09848.x contributor: fullname: Storch – volume: 136 start-page: 628 year: 2000 ident: 10.1016/j.jaad.2010.12.040_bib11 article-title: Flashlamp-pumped pulsed dye laser for hemangiomas in infancy publication-title: Arch Dermatol doi: 10.1001/archderm.136.5.628 contributor: fullname: Poetke – volume: 138 start-page: 1567 year: 2002 ident: 10.1016/j.jaad.2010.12.040_bib6 article-title: Hemangiomas of infancy: clinical characteristics, morphologic subtypes and their relationship to race, ethnicity and sex publication-title: Arch Dermatol doi: 10.1001/archderm.138.12.1567 contributor: fullname: Chiller – volume: 30 start-page: 1013 year: 2009 ident: 10.1016/j.jaad.2010.12.040_bib8 article-title: Efficacy of propranolol in wound healing for hospitalized burn patients publication-title: J Burn Care Res contributor: fullname: Mohammadi – volume: 44 start-page: 962 year: 2001 ident: 10.1016/j.jaad.2010.12.040_bib1 article-title: Ulcerated hemangiomas: clinical characteristics and response to therapy publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2001.112382 contributor: fullname: Kim – volume: 19 start-page: 152 year: 2009 ident: 10.1016/j.jaad.2010.12.040_bib10 article-title: Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases publication-title: Eur J Dermatol doi: 10.1684/ejd.2008.0576 contributor: fullname: Hermans – volume: 124 start-page: 423 year: 2009 ident: 10.1016/j.jaad.2010.12.040_bib5 article-title: Propranolol for severe infantile hemangiomas: follow-up report publication-title: Pediatrics doi: 10.1542/peds.2008-3458 contributor: fullname: Sans – volume: 358 start-page: 2649 year: 2008 ident: 10.1016/j.jaad.2010.12.040_bib4 article-title: Propranolol for severe hemangiomas of infancy publication-title: N Engl J Med doi: 10.1056/NEJMc0708819 contributor: fullname: Léauté-Labrèze |
SSID | ssj0009437 |
Score | 2.3692315 |
Snippet | Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel... Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for... BACKGROUNDUlcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 827 |
SubjectTerms | Adrenergic beta-Antagonists - administration & dosage Adrenergic beta-Antagonists - therapeutic use Biological and medical sciences Child Child, Preschool Dermatology Female General aspects Head and Neck Neoplasms - drug therapy Hemangioma - complications Hemangioma - drug therapy Hemangioma - pathology Humans infantile hemangioma Male Medical sciences propranolol Propranolol - administration & dosage Propranolol - therapeutic use Retrospective Studies Skin Neoplasms - drug therapy Skin Ulcer - drug therapy Skin Ulcer - etiology Treatment Outcome ulceration Wound Healing - drug effects |
Title | Propranolol for treatment of ulcerated infantile hemangiomas |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0190962211000168 https://dx.doi.org/10.1016/j.jaad.2010.12.040 https://www.ncbi.nlm.nih.gov/pubmed/21353332 https://search.proquest.com/docview/862600001 |
Volume | 64 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7ygFIope86bRcdeivuWpbstaCXEBq2LQ2FNpCbGOtRNgTvEu9e-9szs5Y3hD4OvRrLFt-MZj5J30gAb1FiodARc8NQ5No0PjdKF3kTSmLbTgXvt2qLs3p-rj9fVBd7cDLWwrCsMsX-IaZvo3V6Mk1oTleLxfQ7V0GbuuQZDBOXZh8OKR3xXu3h8acv87Pbs3e12lVNc4NUOzPIvC4R_aDw4lVBXgP5c356sMKeUIvDdRd_56PbvHT6CB4mQimOhz4_hr3QPYF7X9OW-VP48O16uaLPUZC7EsRQxU5aLpZRbK4cn6ocvCBPI5ApRgg-xrX7uWDh0DM4P_3442SepysTcqd1sc7R48w4U6GitBNNK2mSqAvXYFG5ysUSqxkWwUsVa0nco1RKo6md8ZHSeBNb9RwOumUXXoIwZSuVrGPTBKlbX3Mqw0phY-qWeEzM4N0IlF0NJ2PYUTJ2aRlWy7BaWVqCNYPZiKUdaz4pSoU-DZneStvTm_Y3s2ZQ7Vre8QxLQf-ff5zcMdmuk-wkFJVUBmK0oaUxxRsl2IXlprfbWR7_PYMXg21vG_M9IUqVR__Zq1dwf1iVZsnkazhYX2_CG6I163YC--9_yUly3hsi2_N8 |
link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgESQrwJlOIDNxQ2jp1sLHFBVasF2gqJVurNmvhRbVVlV83uld_OTB5bVRQOvUZ2bH1jz3y2v7EBPqLETKEj5oYhS7WpfGqUztIq5MS2nQred2qL43J2qr-fFWdbsDfmwrCscvD9vU_vvPXwZTKgOVnO55NfnAVtypxXMExcqntwXxfEfmlQf_59rfMwWm1yprn4kDnTi7wuEH2v7-I9Qd4BuT06PV5iS5jF_rGLf7PRLiodPIUnA50UX_seP4Ot0DyHB0fDgfkL-PLzarGk35GLuxTET8VGWC4WUawvHd-pHLygcUYQk4cQfIlrcz5n2dBLOD3YP9mbpcODCanTOlul6HFqnClQUdCJppa0RNSZqzArXOFijsUUs-CliqUk5pErpdGUzvhIQbyKtXoF282iCW9AmLyWSpaxqoLUtS85kGGhsDJlTSwmJvBpBMou-3sx7CgYu7AMq2VYrcwtwZrAdMTSjhmf5KNCO0yY1krbUkn7l1ETKDY1b4wLSy7_vy3u3jDZppPEWNgnqQTEaENLM4qPSbAJi3VruzUet57A696215X5lRCl8rd37NUHeDg7OTq0h9-Of7yDR_3-NIsnd2B7dbUO74ngrOrdbgD_AVOU9FU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Propranolol+for+treatment+of+ulcerated+infantile+hemangiomas&rft.jtitle=Journal+of+the+American+Academy+of+Dermatology&rft.au=Saint-Jean%2C+M%C3%A9lanie&rft.au=L%C3%A9aut%C3%A9-Labr%C3%A8ze%2C+Christine&rft.au=Mazereeuw-Hautier%2C+Juliette&rft.au=Bodak%2C+Nathalie&rft.date=2011-05-01&rft.issn=0190-9622&rft.volume=64&rft.issue=5&rft.spage=827&rft.epage=832&rft_id=info:doi/10.1016%2Fj.jaad.2010.12.040&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jaad_2010_12_040 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01909622%2FS0190962211X00063%2Fcov150h.gif |